Literature DB >> 26562475

Oct4 is a reliable marker of liver tumor propagating cells in hepatocellular carcinoma.

Guang Wu1,2, George Wilson1,2, Gang Zhou1, Lionel Hebbard1, Jacob George1, Liang Qiao1.   

Abstract

Hepatocellular carcinoma (HCC) is the 6th most common cancer worldwide and the 2nd most common cause of cancer related mortality. The poor prognosis is largely due to the difficulty in early diagnoses and eradication of stem-like cells within HCC, which are termed liver tumor propagating cells (LTPCs). These LTPCs are involved in all stages of tumorigenesis including tumor initiation, progression, and treatment failure. The greatest challenge in understanding these LTPCs is finding effective ways in isolating and characterizing these cells with current methods showing large inter-tumor variability in isolating these cells. Oct4 is a stem cell gene associated with LTPCs and has been shown to be involved in regulating a range of functions in HCC cells associated with LTPC features. In this study we determined the efficacy and reliability in utilizing Oct4 to isolate and characterize LTPCs. We have shown that Oct4 is ubiquitously expressed in all HCC tumors tested whereas other traditional LTPC markers had high intratumor variability in their expression. We then utilized a human Oct4 promoter driving an enhanced green fluorescent protein (EGFP) reporter which showed that Oct4+ cells had all the classic features of LTPCs including increased sphere formation in vitro, tumor forming potential in immunocompromised mice, expression of stemness associated genes, and resistance to Sorafenib which is the major drug used to treat advanced HCC. Based on our findings we have identified Oct4 as a reliable marker of LTPCs and discovered a novel way to isolate and characterize LTPCs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26562475

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  12 in total

1.  eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth.

Authors:  Jan Strnadel; Sunkyu Choi; Ken Fujimura; Huawei Wang; Wei Zhang; Meghan Wyse; Tracy Wright; Emilie Gross; Carlos Peinado; Hyun Woo Park; Jack Bui; Jonathan Kelber; Michael Bouvet; Kun-Liang Guan; Richard L Klemke
Journal:  Cancer Res       Date:  2017-04-05       Impact factor: 12.701

2.  Oct3/4 is potentially useful for the suppression of the proliferation and motility of hepatocellular carcinoma cells.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Naoki Ishige
Journal:  Oncol Lett       Date:  2018-08-10       Impact factor: 2.967

Review 3.  Reporters of Cancer Stem Cells as a Tool for Drug Discovery.

Authors:  Amrutha Mohan; Reshma Raj R; Gayathri Mohan; Padmaja K P; Tessy Thomas Maliekal
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

4.  Human microRNA-299-3p decreases invasive behavior of cancer cells by downregulation of Oct4 expression and causes apoptosis.

Authors:  Axel R Göhring; Stefanie Reuter; Joachim H Clement; Xinlai Cheng; Jannick Theobald; Stefan Wölfl; Ralf Mrowka
Journal:  PLoS One       Date:  2017-04-20       Impact factor: 3.240

5.  Effects of HGF gene polymorphisms and protein expression on transhepatic arterial chemotherapeutic embolism efficacy and prognosis in patients with primary liver cancer.

Authors:  Hai-Yong Chen; Yao-Min Chen; Jian Wu; Fu-Chun Yang; Zhen Lv; Yi-Gang Qian; Shu-Sen Zheng
Journal:  Onco Targets Ther       Date:  2017-02-13       Impact factor: 4.147

6.  WNT/β-Catenin signaling pathway regulates non-tumorigenesis of human embryonic stem cells co-cultured with human umbilical cord mesenchymal stem cells.

Authors:  Yu-Hsun Chang; Tang-Yuan Chu; Dah-Ching Ding
Journal:  Sci Rep       Date:  2017-02-03       Impact factor: 4.379

Review 7.  Cancer stem cells of hepatocellular carcinoma.

Authors:  Kewei Wang; Dianjun Sun
Journal:  Oncotarget       Date:  2018-05-01

8.  Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma.

Authors:  Xiaoge Gao; Pin Jiang; Qian Zhang; Qian Liu; Shuangshuang Jiang; Ling Liu; Maomao Guo; Qian Cheng; Junnian Zheng; Hong Yao
Journal:  J Exp Clin Cancer Res       Date:  2019-08-19

Review 9.  Markers and Reporters to Reveal the Hierarchy in Heterogeneous Cancer Stem Cells.

Authors:  Amrutha Mohan; Reshma Raj Rajan; Gayathri Mohan; Padmaja Kollenchery Puthenveettil; Tessy Thomas Maliekal
Journal:  Front Cell Dev Biol       Date:  2021-06-03

10.  Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma.

Authors:  Chuan Xing Wu; Xiao Qi Wang; Siu Ho Chok; Kwan Man; Simon Hing Yin Tsang; Albert Chi Yan Chan; Ka Wing Ma; Wei Xia; Tan To Cheung
Journal:  Theranostics       Date:  2018-06-13       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.